See more : NextNav Inc. (NN) Income Statement Analysis – Financial Results
Complete financial analysis of Immune Therapeutics, Inc. (IMUN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immune Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Satrix Global Aggregate Bond Feeder Portfolio (STXGBD.JO) Income Statement Analysis – Financial Results
- CellaVision AB (publ) (CEVI.ST) Income Statement Analysis – Financial Results
- Gray Television, Inc. (GTN) Income Statement Analysis – Financial Results
- ASM Group S.A. (ASM.WA) Income Statement Analysis – Financial Results
- Eckert & Ziegler Strahlen- und Medizintechnik AG (0NZY.L) Income Statement Analysis – Financial Results
Immune Therapeutics, Inc. (IMUN)
About Immune Therapeutics, Inc.
Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is headquartered in Orlando, Florida.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 113.50K | 0.00 | 3.46K | 16.20K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 47.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 65.83K | 0.00 | 3.46K | 16.20K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 58.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 14.24K | 152.67K | 126.26K | 336.11K | 144.10K | 399.44K | 444.17K | 977.20K | 7.54M | 22.02M | 4.96M |
| General & Administrative | 0.00 | 585.50K | 760.13K | 2.50M | 4.00M | 4.92M | 9.10M | 9.08M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 3.23M | 0.00 | -401.00 | -106.59K | 0.00 | 0.00 | 0.00 |
| SG&A | 1.15M | 585.50K | 760.13K | 2.50M | 4.00M | 4.92M | 9.10M | 8.97M | 24.94M | 71.10M | 48.56M |
| Other Expenses | 3.17M | 0.00 | 639.00 | 2.07K | -2.79M | 826.00 | 0.00 | 0.00 | 2.88M | 2.85M | 1.57M |
| Operating Expenses | 1.16M | 738.17K | 887.03K | 2.84M | 4.15M | 5.32M | 9.54M | 10.55M | 35.36M | 95.98M | 55.09M |
| Cost & Expenses | 1.16M | 738.17K | 887.03K | 2.84M | 4.20M | 5.32M | 9.54M | 10.55M | 35.36M | 95.98M | 55.09M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 120.40K | 210.92K | 479.93K | 894.17K | 1.18M | 1.22M | 3.45M | 270.99K | 388.22K | 1.44M | 27.00K |
| Depreciation & Amortization | 520.15K | 2.65M | -172.48K | 384.38K | 1.73K | 826.00 | 1.56K | 594.79K | 2.88M | 2.85M | 1.57M |
| EBITDA | -643.34K | 1.91M | -1.06M | -2.45M | -7.25M | -5.32M | -9.54M | -9.94M | -32.48M | -93.13M | -53.52M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -6,388.07% | 0.00% | -275,472.28% | -61,342.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.16M | -738.17K | -887.03K | -2.84M | -4.08M | -5.91M | -14.27M | -15.80M | -45.26M | -95.98M | -153.09M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -3,598.96% | 0.00% | -412,124.98% | -97,566.77% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.37M | 4.32M | 2.48M | -558.61K | -4.54M | -2.02M | -5.55M | -1.15M | -4.67M | -10.08M | -22.13M |
| Income Before Tax | -3.54M | 3.59M | 1.59M | -3.40M | -8.63M | -7.93M | -19.82M | -16.95M | -49.94M | -106.06M | -175.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -7,599.66% | 0.00% | -572,307.28% | -104,645.62% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.25M | 210.92K | 479.93K | 1.28M | -3.36M | 598.77K | 3.15M | -364.67K | -1.30M | 1.44M | -204.35K |
| Net Income | -5.79M | 3.59M | 1.11M | -4.67M | -8.18M | -7.32M | -19.52M | -16.31M | -48.25M | -106.06M | -174.99M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -7,202.84% | 0.00% | -563,713.57% | -100,721.10% | 0.00% | 0.00% | 0.00% |
| EPS | -0.16 | 0.38 | 2.40 | -10.44 | -19.03 | -22.81 | -90.09 | -106.45 | -489.84 | -1.85K | -6.84K |
| EPS Diluted | -0.16 | 0.38 | 2.40 | -10.44 | -19.03 | -22.81 | -90.09 | -106.45 | -489.84 | -1.85K | -6.84K |
| Weighted Avg Shares Out | 36.29M | 9.39M | 461.19K | 447.53K | 429.66K | 320.72K | 216.69K | 153.25K | 98.51K | 57.23K | 25.58K |
| Weighted Avg Shares Out (Dil) | 36.29M | 9.39M | 461.19K | 447.53K | 429.66K | 320.72K | 216.69K | 153.25K | 98.51K | 57.23K | 25.58K |
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky
Orlando, FL, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp (OTC Pink: IMUN) (“Biostax”), a hub and spoke biotech development engine, sadly announces the passing of H. Louis Salomonksy, a dedicated member of its Board of...
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
Orlando, FL, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp . (OTC Pink: IMUN) (“Biostax”), a hub-and-spoke biotech development engine, announces the signing of a research collaboration agreement with Immgenuity, Inc . The joint research will...
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
Orlando, FL, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. d/b/a Biostax Corp. (OTC Pink: IMUN) ("Biostax"), a hub-and-spoke biotech development engine, announces that they have accepted the transfer of three Investigational New Drug Applications (IND) for the drug...
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! The post The 10 Most Shorted Stocks Right Now for Friday, Dec. 17 appeared first on...
Immune Therapeutics Announces Restructuring Plan
Orlando, Florida , June 04, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the "Company") announced today that the Company has received and signed a non-binding term sheet to enter into an agreement that would provide working capital and...
Immune Therapeutics FINRA Approval for 1:1000 Reverse Stock Split
Orlando, Florida , May 11, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the "Company") announced today that FINRA has processed a reverse split of 1-for 1,000 of the issued and outstanding stock. The reverse stock split was completed...
Source: https://incomestatements.info
Category: Stock Reports